Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LMAO $MDBX it continues
Doesn't even matter since so far this is a dilution machine with empty promises
start the buy back and turn off the faucet and prove me wrong
financing my a$$, so far only at the expense of share holders
dilution machine with sub penny written all over it
Trina did this before, that crafty ole stock man that he was
wash rinse repeat
but no SEC filings or audits yet - so its unconfirmed
lmao $MDBX
they expecting some options trading? wouldn't that be nice if it qualified ;)
$AEYE
appreciate the info - anticipation building up for trading.
Im looking forward to it - sitting back enjoying the weather.
$AEYE
Good Morning - Nice day out, hoping traders are coming out in a good mood.
$BAC
As far as i see it - I would believe MM's do not become shareholders of record.
Good Morning :) Beautiful day in NYC
over reaction imo - numbers are up and $BAC is turning its business around
great day to add - interested to see what the volume is once the "daily bottom" sets in
could see some boats getting loaded as opposed to dumpage
this will be back above $12 "shortly" - numbers are up and this is Bank of America, not some five and dime local bank
they have turned it around and i expect the stock to do the same, or should i say continue to do the same cause this uptrend is pretty solid
all in my opinion of course :P
$BAC
total over reaction $BAC is a buy imo
damn if they had it in NYC id be there!
$CBIS
nice volume and uptick today - good healthy action
would love to see a positive earnings coupled with 200-300M volume day :)
$BAC
it's all relatively baked in - real movement will come from either FDA or Feds
this company is poised to benefit the least from either IMO
but sector momo will always have it's effects
IMO
So here is the corporate test of honesty
after today's PR (perhaps end of week or next)- I'm curious to see the share structure
if it went up again, then I call shenanigans and malarkey
if not, then something could be brewing
IMO
haha that scams a sand box pump :p
a little early for ;) $MDBX
publicity and awareness perhaps
not only for the company but more importantly for the cause
$CBIS
lol work has me distracted so it's still exciting for me
another day or so and I'll start getting bored....or anxious might be a better word
$CMGO
proceed with caution in regards to TTIN
from my experience with CEO and company
trade if you like but dont marry it unless its bringing something to the table in regards to revenue and profits
this company had products and patents before that took it no where
now post R/S and silent period it seems to be trying something again
looks like $CMGO is waiting on AudioEye
the wait is exciting
News - The X-Change Corporation Announces the Sacred Cow Production presentation of 'AMERICAN DRUG WAR 2: Cannabis Destiny,' a film by Kevin Booth National Release on June 6, 2013, with Invitation-Only, Private VIP Viewing on Thursday, April 18, 2013 at Casselman's in Denver, Colorado)
DALLAS, April 16, 2013 /PRNewswire via COMTEX/ -- X-Change Corp. (NASDAQ OTC:
XCHC), a U.S. Company specializing in cannabinoid formulation-based health and
wellness solutions through its Phytiva Brand product lines, is excited to
announce that 'AMERICAN DRUG WAR 2: Cannabis Destiny,' a film by Kevin Booth and
produced by Sacred Cow Productions, will have its national release on June 6,
2013 in Denver, Colorado. There will be a VIP screening event on Thursday, April
18, at Casselman's in Denver, Colorado to kick off the 'High Times' Cannabis Cup
weekend. The event also includes a Cloverleaf University Class taught by Ed
Rosenthal as well as musical performance.
During the pre-production and research phase for 'AMERICAN DRUG WAR 2: Cannabis
Destiny,' award-winning filmmaker Kevin Booth searched for a leading voice to
shed light on medical cannabinoid formulations to help inform the general
public. The first installment of 'American Drug War' had premiered on Showtime
in 2008 and featured interviews with University of Colorado Professor Robert
Melamede, PhD, who has been working on FDA-track cannabinoid medicines through a
publicly traded company, Cannabis Science, Inc., after decades of activism and
scientific research. Dr. Melamede continues his efforts to bring the actual
cannabis plant derivative into the modern pharmacopeia and is again featured in
the new film.
X-Change Corporation is picking up this film awareness effort and other projects
that Cannabis Science had begun over the last twelve months, as Cannabis
Science's sole direction has evolved to cannabinoid drug development, clinical
trials, and FDA and other regulatory approval for its drugs, including its
CS_TATI-1 formulation to treat Kaposi's Sarcoma.
X-Change Corporation is also in the process of updating its website with actual
testimonials and photographs of the profound efficacy of treating skin cancer
and other critical ailments with topical and ingested cannabis extracts. The
precise launch date of the website with this information will be announced soon.
A trailer for 'AMERICAN DRUG WAR 2' can be seen here:
http://www.youtube.com/user/AmericanDrugWar
Already gaining key support, Law Enforcement Against Prohibition (LEAP) called
'AMERICAN DRUG WAR 2' "the most powerful and important documentary to date."
'AMERICAN DRUG WAR 2' Director Kevin Booth navigates through the cutting edge of
cannabinoid research showing a child's foster parent managing the child's
court-order to take powerful mind-altering drugs.
The film's distribution is being headed up by Gravitas Venture, a trend setting
company that specializes in world-wide video-on-demand as well as a theatrical
release through on-line start up TUGG.com. "Basically anyone - anywhere can go
to TUGG.com and request a screening in their own area at their favorite theater.
It's a new concept revolutionizing the industry called 'Theaters on Demand.'
Once your theater has sold approximately 50 tickets - your event is booked. It's
free and allows fans not only to participate, but also to earn a little extra to
give back to their own local legalization efforts. Simply go to
http://www.tugg.com/titles/american-drug-war-2 and become one of our hosts,"
stated Kevin Booth, who hopes to blanket the country with the film on June 6,
2013.
The film is a sequel to the original 'American Drug War' film which not only
appeared on Showtime but also won three film festival awards including 'Best
Documentary' at the Silver Lake Film Festival, Los Angeles, CA in 2007, 'Best
Documentary' at the Artivist, Hollywood, CA in 2007, and 'Best Documentary' at
Evil City, East Village, in New York City in 2006.
"It is an incredible experience to work with Kevin Booth and his team. Our team
would like to thank them for the opportunity to be involved both by giving
illustrations in the film, and by working behind the scenes in the overall
production of the film. We look forward to seeing the success of the film and
continue to be a marketing partner going forward as the film is shown in
theaters and on Video On Demand globally," stated Robert Kane, President & CEO
of X-Change Corp. "After helping with Kevin's business plan for this film, it's
an honor to be in the documentary and see the project come to fruition on the
big screen," Mr. Kane added.
About the original "American Drug War"
Thirty-five years after Nixon started the war on drugs, we have over one million
non-violent drug offenders living behind bars.
The War on Drugs has become the longest and most costly war in American history;
the question has become, how much more can the country endure? Inspired by the
death of four family members from "legal drugs," Texas filmmaker Kevin Booth
sets out to discover why the Drug War has become such a big failure. Three and a
half years in the making, the film follows gang members, former DEA agents, CIA
officers, narcotics officers, judges, politicians, prisoners and celebrities.
Most notably the film befriends Freeway Ricky Ross, the man many accuse for
starting the Crack epidemic, who after being arrested discovered that his
cocaine source had been working for the CIA.
'American Drug War' shows how money, power and greed have corrupted not just
drug pushers, but also an entire government. More importantly, it shows what can
be done about it. This is not some 'pro-drug' stoner film, but a collection of
expert testimonials from the ground troops on the front lines of the drug war,
the ones who are fighting it and the ones who are living it.
About Phytiva Brand Product Lines
X-Change Corp. expects to develop and launch various innovative Phytiva Brand
product lines. The first is the Phytiva Brand European Line, which is an
inventive line that is a hybrid of a proven, existing product line that has been
well-managed and conservatively-run for over a decade with a Cannabinoid-based
product line, utilizing the unique and potent benefits of Cannabinoids.
Phytiva's revolutionary formulations target not just the symptom, but also the
cause. Cannabinoids and their sources constitute an ideal base for therapeutic
solutions and have been utilized for centuries in skin and other remedies.
About The X-Change Corporation
X-Change Corp. is U.S. boutique Company whose niche is cannabinoid-based
extracts and products that target critical ailment, cosmeceutical,
nutraceutical, and social usage solutions through multiple Phytiva Brand product
lines, products, and services. These new Phytiva lines will be launched with
cannabinoid-based formulations through the launching of a combination of retail
and wholesale products, medical cannabis dispensaries, cannabis research in
clinics and laboratories, and other legal state and foreign grow operations, on
a jurisdiction by jurisdiction approved basis.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act
of 1934. A statement containing works such as "anticipate," "seek," intend,"
"believe," "plan," "estimate," "expect," "project," "plan," or similar phrases
may be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur. Factors that
could cause or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabinoid-based products.
X-Change Corp. does not undertake any duty or does not intend to update the
results of these forward-looking statements.
X-Change Corp.President & CEORobert
KaneInfo@phytiva.comwww.phytiva.com1.866.326.5595
SOURCE X-Change Corp.
http://rt.prnewswire.com/rt.gif?NewsItemId=LA95536&Transmission_Id=201304161146PR_NEWS_USPR_____LA95536&DateId=20130416
www.prnewswire.com
Copyright (C) 2013 PR Newswire. All rights reserved
-0-
KEYWORD: Texas
Colorado
INDUSTRY KEYWORD: ENT
FLM
HEA
SPM
OTC
Source: Comtext Market News
Compliments of Scottrade.com
News - The X-Change Corporation Announces the Sacred Cow Production presentation of 'AMERICAN DRUG WAR 2: Cannabis Destiny,' a film by Kevin Booth National Release on June 6, 2013, with Invitation-Only, Private VIP Viewing on Thursday, April 18, 2013 at Casselman's in Denver, Colorado)
DALLAS, April 16, 2013 /PRNewswire via COMTEX/ -- X-Change Corp. (NASDAQ OTC:
XCHC), a U.S. Company specializing in cannabinoid formulation-based health and
wellness solutions through its Phytiva Brand product lines, is excited to
announce that 'AMERICAN DRUG WAR 2: Cannabis Destiny,' a film by Kevin Booth and
produced by Sacred Cow Productions, will have its national release on June 6,
2013 in Denver, Colorado. There will be a VIP screening event on Thursday, April
18, at Casselman's in Denver, Colorado to kick off the 'High Times' Cannabis Cup
weekend. The event also includes a Cloverleaf University Class taught by Ed
Rosenthal as well as musical performance.
During the pre-production and research phase for 'AMERICAN DRUG WAR 2: Cannabis
Destiny,' award-winning filmmaker Kevin Booth searched for a leading voice to
shed light on medical cannabinoid formulations to help inform the general
public. The first installment of 'American Drug War' had premiered on Showtime
in 2008 and featured interviews with University of Colorado Professor Robert
Melamede, PhD, who has been working on FDA-track cannabinoid medicines through a
publicly traded company, Cannabis Science, Inc., after decades of activism and
scientific research. Dr. Melamede continues his efforts to bring the actual
cannabis plant derivative into the modern pharmacopeia and is again featured in
the new film.
X-Change Corporation is picking up this film awareness effort and other projects
that Cannabis Science had begun over the last twelve months, as Cannabis
Science's sole direction has evolved to cannabinoid drug development, clinical
trials, and FDA and other regulatory approval for its drugs, including its
CS_TATI-1 formulation to treat Kaposi's Sarcoma.
X-Change Corporation is also in the process of updating its website with actual
testimonials and photographs of the profound efficacy of treating skin cancer
and other critical ailments with topical and ingested cannabis extracts. The
precise launch date of the website with this information will be announced soon.
A trailer for 'AMERICAN DRUG WAR 2' can be seen here:
http://www.youtube.com/user/AmericanDrugWar
Already gaining key support, Law Enforcement Against Prohibition (LEAP) called
'AMERICAN DRUG WAR 2' "the most powerful and important documentary to date."
'AMERICAN DRUG WAR 2' Director Kevin Booth navigates through the cutting edge of
cannabinoid research showing a child's foster parent managing the child's
court-order to take powerful mind-altering drugs.
The film's distribution is being headed up by Gravitas Venture, a trend setting
company that specializes in world-wide video-on-demand as well as a theatrical
release through on-line start up TUGG.com. "Basically anyone - anywhere can go
to TUGG.com and request a screening in their own area at their favorite theater.
It's a new concept revolutionizing the industry called 'Theaters on Demand.'
Once your theater has sold approximately 50 tickets - your event is booked. It's
free and allows fans not only to participate, but also to earn a little extra to
give back to their own local legalization efforts. Simply go to
http://www.tugg.com/titles/american-drug-war-2 and become one of our hosts,"
stated Kevin Booth, who hopes to blanket the country with the film on June 6,
2013.
The film is a sequel to the original 'American Drug War' film which not only
appeared on Showtime but also won three film festival awards including 'Best
Documentary' at the Silver Lake Film Festival, Los Angeles, CA in 2007, 'Best
Documentary' at the Artivist, Hollywood, CA in 2007, and 'Best Documentary' at
Evil City, East Village, in New York City in 2006.
"It is an incredible experience to work with Kevin Booth and his team. Our team
would like to thank them for the opportunity to be involved both by giving
illustrations in the film, and by working behind the scenes in the overall
production of the film. We look forward to seeing the success of the film and
continue to be a marketing partner going forward as the film is shown in
theaters and on Video On Demand globally," stated Robert Kane, President & CEO
of X-Change Corp. "After helping with Kevin's business plan for this film, it's
an honor to be in the documentary and see the project come to fruition on the
big screen," Mr. Kane added.
About the original "American Drug War"
Thirty-five years after Nixon started the war on drugs, we have over one million
non-violent drug offenders living behind bars.
The War on Drugs has become the longest and most costly war in American history;
the question has become, how much more can the country endure? Inspired by the
death of four family members from "legal drugs," Texas filmmaker Kevin Booth
sets out to discover why the Drug War has become such a big failure. Three and a
half years in the making, the film follows gang members, former DEA agents, CIA
officers, narcotics officers, judges, politicians, prisoners and celebrities.
Most notably the film befriends Freeway Ricky Ross, the man many accuse for
starting the Crack epidemic, who after being arrested discovered that his
cocaine source had been working for the CIA.
'American Drug War' shows how money, power and greed have corrupted not just
drug pushers, but also an entire government. More importantly, it shows what can
be done about it. This is not some 'pro-drug' stoner film, but a collection of
expert testimonials from the ground troops on the front lines of the drug war,
the ones who are fighting it and the ones who are living it.
About Phytiva Brand Product Lines
X-Change Corp. expects to develop and launch various innovative Phytiva Brand
product lines. The first is the Phytiva Brand European Line, which is an
inventive line that is a hybrid of a proven, existing product line that has been
well-managed and conservatively-run for over a decade with a Cannabinoid-based
product line, utilizing the unique and potent benefits of Cannabinoids.
Phytiva's revolutionary formulations target not just the symptom, but also the
cause. Cannabinoids and their sources constitute an ideal base for therapeutic
solutions and have been utilized for centuries in skin and other remedies.
About The X-Change Corporation
X-Change Corp. is U.S. boutique Company whose niche is cannabinoid-based
extracts and products that target critical ailment, cosmeceutical,
nutraceutical, and social usage solutions through multiple Phytiva Brand product
lines, products, and services. These new Phytiva lines will be launched with
cannabinoid-based formulations through the launching of a combination of retail
and wholesale products, medical cannabis dispensaries, cannabis research in
clinics and laboratories, and other legal state and foreign grow operations, on
a jurisdiction by jurisdiction approved basis.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act
of 1934. A statement containing works such as "anticipate," "seek," intend,"
"believe," "plan," "estimate," "expect," "project," "plan," or similar phrases
may be deemed "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur. Factors that
could cause or contribute to such differences include the future U.S. and global
economies, the impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabinoid-based products.
X-Change Corp. does not undertake any duty or does not intend to update the
results of these forward-looking statements.
X-Change Corp.President & CEORobert
KaneInfo@phytiva.comwww.phytiva.com1.866.326.5595
SOURCE X-Change Corp.
http://rt.prnewswire.com/rt.gif?NewsItemId=LA95536&Transmission_Id=201304161146PR_NEWS_USPR_____LA95536&DateId=20130416
www.prnewswire.com
Copyright (C) 2013 PR Newswire. All rights reserved
-0-
KEYWORD: Texas
Colorado
INDUSTRY KEYWORD: ENT
FLM
HEA
SPM
OTC
Source: Comtext Market News
Compliments of Scottrade.com
oh snap - a new movie/documentary with CBIS coming soon
no one cares about the gum or soda - show me meds
$CBIS
nice action out of the gate $BAC
That would require real work lmao
instead of cooks they would need chemists and doctors
I know where they could find those peeps those ;p
Haha jumped on it like sharks
$AEYE is exciting :)
should be interesting - I'd gladly take this as healthy consolidation
a good earnings report could def help the cause
well the latest developments from my perspective is the following
-claimed buy back followed immediately by dilution
-war on shorters (ugghhh)
-claimed possible funding followed by dilution
time for "action jackson" to step up or let those leopard spots be permanent
seen this song and dance before, a different outcome would be nice but I thought someone once told me that was the definition of crazy lol
$ATYG
I've been hearing rumblings but from my understanding its not the physical tablet but that platform it runs on that will also be for PC's
a cross device platform syncing all devices.....or to that extent
If its true, then IMO move over apple
$CMGO spin off AudioEye $AEYE
should start trading soon
Opening action should be interesting
$CMGO spin off AudioEye $AEYE
should start trading soon
Opening action should be interesting
can't wait to see opening action $AEYE
$SEEK - good morning
looking forward to seeing $AEYE action
$AEYE Trading on OTCQB and the OTC Bulletin Board may be volatile and sporadic, which could depress the market price of our common shares and make it difficult for our stockholders to resell their shares.
Our common shares are listed to be quoted on the OTCQB and OTC Bulletin Board services effective April 15, 2013. Trading in shares quoted on the OTCQB and OTC Bulletin Board is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. This volatility could depress the market price of shares of our common stock for reasons unrelated to operating performance. Moreover, the OTCQB and OTC Bulletin Board are not stock exchanges, and trading of securities on the OTCQB and OTC Bulletin Board are often more sporadic than the trading of securities listed on a quotation system like NASDAQ or a stock exchange like Amex. Accordingly, stockholders may have difficulty reselling shares of our common stock.
A substantial number of shares of our common stock may be sold into the market at any time. This could cause the market price of our common stock to drop significantly, even if our business is doing well.
All of the 1,500,259 shares of our common stock that were registered pursuant to our registration statement that was declared effective as of January 29, 2013 are freely tradable without restrictions or further registration under the federal securities laws, except for shares owned by our “affiliates” as that term is defined in Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”). The remaining shares of common stock outstanding after the effective date of our registration statement, including the shares issued in the Separation, are restricted securities as defined in Rule 144. Restricted securities may be sold in the U.S. public market only if registered under the Securities Act or if they qualify for an exemption from registration, including by reason of Rule 144. All of our restricted shares are eligible for sale in the public market beginning after the effective date, provided that such restricted shares have been held for at least six months, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 for shares held by our affiliates. Sales of a substantial number of shares of our common stock, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.
Our share is a penny stock; trading of shares of our common stock may be restricted by the SEC’s penny stock regulations, which may limit a stockholder’s ability to buy and sell our shares.
Our share is a penny stock. The SEC has adopted Rule 15g-9 which generally defines “penny stock” to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and “accredited investors.” The term “accredited investor” refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC, which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the shares that are subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in and limit the marketability of our common shares.
SOURCE:
http://www.secinfo.com/d1AaJk.x18p.htm#1stPage
im not sure, id have to crunch the number
$AEYE
right above the table of contents
$AEYE